Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.
about
Heart failure in chemotherapy-related cardiomyopathy: Can exercise make a difference?Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicityThe emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitorsPodocyte developmental defects caused by adriamycin in zebrafish embryos and larvae: a novel model of glomerular damageNeurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: A systematic reviewPalliative Care in Older Patients With CancerRecent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsSex-specific cardiac cardiolipin remodelling after doxorubicin treatmentSynthesis and biological evaluation of novel folic acid receptor-targeted, β-cyclodextrin-based drug complexes for cancer treatmentAttenuation of doxorubicin-induced cardiotoxicity by mdivi-1: a mitochondrial division/mitophagy inhibitorIMD-0354 targets breast cancer stem cells: a novel approach for an adjuvant to chemotherapy to prevent multidrug resistance in a murine modelROCK1 deficiency enhances protective effects of antioxidants against apoptosis and cell detachmentDissecting the Mechanisms of Doxorubicin and Oxidative Stress-Induced Cytotoxicity: The Involvement of Actin Cytoskeleton and ROCK1A Biophysical Systems Approach to Identifying the Pathways of Acute and Chronic Doxorubicin Mitochondrial CardiotoxicityDoxorubicin impairs the insulin-like growth factor-1 system and causes insulin-like growth factor-1 resistance in cardiomyocytes.Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Perfluorocarbon nanoparticles: evolution of a multimodality and multifunctional imaging agent.Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase.Presence of Cx43 in extracellular vesicles reduces the cardiotoxicity of the anti-tumour therapeutic approach with doxorubicinNrf2 deficiency exaggerates doxorubicin-induced cardiotoxicity and cardiac dysfunction.The long non-coding RNA H19 promotes cardiomyocyte apoptosis in dilated cardiomyopathy.Berberis vulgaris and its constituent berberine as antidotes and protective agents against natural or chemical toxicities.Early transcriptional alteration of histone deacetylases in a murine model of doxorubicin-induced cardiomyopathy.Mice lacking mitochondrial ferritin are more sensitive to doxorubicin-mediated cardiotoxicity.P53 inhibition exacerbates late-stage anthracycline cardiotoxicity.Calorie restriction combined with resveratrol induces autophagy and protects 26-month-old rat hearts from doxorubicin-induced toxicityConcomitant low-dose doxorubicin treatment and exerciseUrotensin II inhibits doxorubicin-induced human umbilical vein endothelial cell death by modulating ATF expression and via the ERK and Akt pathwayPotential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy.Thymol and Carvacrol Prevent Doxorubicin-Induced Cardiotoxicity by Abrogation of Oxidative Stress, Inflammation, and Apoptosis in Rats.The human amniotic fluid stem cell secretome effectively counteracts doxorubicin-induced cardiotoxicity.Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro.Assessing the translatability of in vivo cardiotoxicity mechanisms to in vitro models using causal reasoning.Clinical significance of ischemia-modified albumin in the diagnosis of doxorubicin-induced myocardial injury in breast cancer patients.Anthracycline-containing chemotherapy causes long-term impairment of mitochondrial respiration and increased reactive oxygen species release in skeletal muscle.Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance.Shengmai injection improved doxorubicin-induced cardiomyopathy by alleviating myocardial endoplasmic reticulum stress and caspase-12 dependent apoptosis.Anthracycline treatment and ventricular remodeling in left ventricular assist device patients.MicroRNA-532-3p regulates mitochondrial fission through targeting apoptosis repressor with caspase recruitment domain in doxorubicin cardiotoxicity.Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms.
P2860
Q26740352-2CB00DA9-56BC-4109-979B-6E2070CCC784Q26744675-BA283054-C170-457D-B648-B98D371913EBQ27011540-9579C6C0-9411-4253-BAA1-854253547B3DQ27329863-7A42C21D-3D7E-422C-93C4-D187AFE96851Q28084550-BBFD73A1-ADEC-4E25-A782-44FC12FF8B0DQ28085144-2984A3BA-60C9-4DE8-8618-62A4109651D2Q28087776-DBC50705-1130-409E-A7CB-A91BB7980417Q28391344-C16A8D28-4188-4085-A270-A5E3465485F9Q28487569-43AE4B69-D304-401F-B6FC-0D1EEEBF1BD6Q28534483-CEC0E733-1B5E-4386-8674-93FC0C8361F4Q28535709-FC522A55-6481-4469-A847-D0107D29B743Q28540406-C174F531-C0FF-4385-B0B0-BAD3F85ED63EQ28546141-6C079595-6631-4AE7-8052-A519B1E6D270Q28553631-2C159420-78FA-426F-A6DC-D71609847C58Q30411254-C77B42DC-123E-4567-AB93-AC7B31E58AC0Q30426853-12DF318F-F82E-408B-B9A0-222264F7ED7FQ30434964-9337BAAD-32F8-45FB-8B15-28C8057FECE4Q30628082-E7DE3EB1-28CA-4304-9088-8705B6AEAD3CQ30817598-72BB9E07-4B50-433D-B1BF-AD51FD12FB50Q33660939-3C1F7B61-C620-4179-B34C-F78E2D856EA8Q33709796-77ECE856-590F-4F1D-9C59-2D1D78405D2EQ33819605-6E79D111-E7E6-4D5F-905A-66C0807001BDQ33853732-81C9DA60-D8BE-4863-97C6-1AF5C683EB2EQ33985016-50D9BF1A-A59F-4292-A5D8-07F3CE7D06DDQ34048273-39090B79-4A8C-41A0-A4C1-72BF093D862AQ34098331-91516503-267F-4DE6-BA63-AB656AFE38D9Q34201221-CAF7F250-3BAD-4631-8249-A22717736C96Q34275989-82C9FB41-4C01-4E59-BC2F-77230CF4DCEDQ34333236-99BD0A74-F786-4BB6-9F48-664BC1392935Q34494900-07014318-A620-474A-B76F-D153A8E1C514Q34534895-67C22064-E576-4805-88EA-109B1FAE32F9Q34749618-EB72C15F-3B0A-4BFA-996B-2A18DCE33BDBQ34980120-70EDCCD2-92CB-46B3-B95A-A8DE2E30ECA8Q35041318-3B08B537-962B-4366-BAE3-B966A3B69814Q35138773-0764274F-4ECC-49A9-AA28-16C285C647B1Q35189961-E92E282D-BECE-49DA-97A2-7124D9677CE6Q35206783-5A43E513-3498-453E-A777-7DF11890B71AQ35246219-97500CDA-89D4-4A09-AE1D-417346B4961AQ35274471-15C9BE9C-7154-42B8-A6B1-8147E608A0E1Q35296244-78672AED-73ED-4825-AD0D-B2BB6FE527A6
P2860
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.
@en
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.
@nl
type
label
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.
@en
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.
@nl
prefLabel
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.
@en
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.
@nl
P2093
P1476
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.
@en
P2093
An L Moens
Harry J Crijns
Kathleen L Gabrielson
Stefan Janssens
Yanti Octavia
P304
P356
10.1016/J.YJMCC.2012.03.006
P577
2012-03-21T00:00:00Z